The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review


Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Rheumatology


Psychiatry related information on Rheumatology


High impact information on Rheumatology

  • Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group [10].
  • Clinical response was defined as the percent improvement in disease activity according to the criteria of the American College of Rheumatology. Bone erosion and joint-space narrowing were measured radiographically and scored with use of the Sharp scale [11].
  • The primary measure of clinical response was the American College of Rheumatology criteria for a 20 percent improvement in measures of disease activity (ACR 20) at 24 weeks [12].
  • Thirty-six patients (48 percent) in the cyclosporine group and 12 patients (16 percent) in the placebo group (P < 0.001) met the 1993 criteria for improvement of the American College of Rheumatology (more than 20 percent improvement in the numbers of both swollen and tender joints and improvement in three of five other variables) [13].
  • We also manually searched review articles, manuscripts, and supplements from rheumatology and OA journals and sought unpublished data by contacting content experts, study authors, and manufacturers of glucosamine or chondroitin [14].

Chemical compound and disease context of Rheumatology

  • The results of IMT measurement were not correlated with the patients' age, disease duration, SLE Disease Activity Index (SLEDAI) score, Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index (DI) score, laboratory indicators of lupus activity, or cumulative prednisone dose [15].
  • METHODS: Patients with WG were selected according to both Chapel Hill Consensus Conference definition and American College of Rheumatology (ACR) classification criteria in 500 Chinese patients with ANCA-associated systemic vasculitides [16].
  • CONCLUSIONS: Treatment of patients with RA in a community rheumatology practice with hydroxychloroquine has a low probability of long term continuation, mostly because of inadequate control of disease manifestations rather than toxicity [17].
  • Hypoxia inducible factor (HIF) in rheumatology: low O2! See what HIF can do [18]!
  • Screening for proteinuria in a rheumatology clinic: comparison of dipstick testing, 24 hour urine quantitative protein, and protein/creatinine ratio in random urine samples [19].

Biological context of Rheumatology

  • OBJECTIVE: To compare the content of clinical, occupation-based instruments that are used in adult rheumatology and musculoskeletal rehabilitation in occupational therapy based on the International Classification of Functioning, Disability and Health (ICF) [20].
  • At presentation, 120 patients fulfilled the American College of Rheumatology 1987 criteria for RA, 64% of whom possessed the conserved base sequences, compared with 45% of 347 healthy controls (P < 0.001) and with 56% of 57 patients with other inflammatory arthritis (P not significant) [21].
  • METHODS: IL10.R genotypes were determined by semi-automated DNA sequencing technology in 186 UK Caucasians and 138 South Africans of Zulu or Sotho origin, fulfilling the 1987 American College of Rheumatology (ACR) criteria for RA [22].
  • A postal questionnaire among 41 rheumatology and 33 ophthalmology centres showed 2 patients who developed impaired vision as a result of treatment with chloroquine in a daily dose not exceeding 250 mg [23].
  • METHODS: A retrospective review of all cases of dermatomyositis treated with methotrexate in a dermatology and rheumatology referral practice was conducted [24].

Anatomical context of Rheumatology


Associations of Rheumatology with chemical compounds

  • Methotrexate in resistant juvenile rheumatoid arthritis. Results of the U.S.A.-U.S.S.R. double-blind, placebo-controlled trial. The Pediatric Rheumatology Collaborative Study Group and The Cooperative Children's Study Group [29].
  • The American Board of Internal Medicine recertification program in rheumatology [30].
  • At followup, RA was in remission (American College of Rheumatology criteria) without disease-modifying antirheumatic drug (DMARD) or steroid therapy in 8 of the patients originally treated with minocycline compared with 1 patient in the placebo group (P = 0.02) [31].
  • Patients were assessed for adverse effects, pharmacokinetic measurements of leflunomide and methotrexate, and clinical response by American College of Rheumatology (ACR) 20% response criteria [32].
  • The primary end points of the study were 1) the percentage of patients with an American College of Rheumatology (ACR) 50% improvement (ACR50) response at 2 years, and 2) the dosage of prednisone at 2 years [33].

Gene context of Rheumatology

  • In the subset of patients fulfilling the 20% response criteria of the American College of Rheumatology, a more pronounced reduction in the expression of ICAM-1, VCAM-1, IL-1beta, and MMP-1 was found compared with the nonresponders [34].
  • METHODS: 123 patients with active RA were treated with etanercept and response rates were determined after three months using American College of Rheumatology (ACR)20 and disease activity score (DAS)28 response criteria [35].
  • The most recent OA guidelines from the American College of Rheumatology were published in 2000 because new therapies such as the COX-2-selective inhibitors had been introduced for the management of OA [36].
  • A decrease in serum COMP was seen both in ACR20 responders (patients meeting the American College of Rheumatology criteria for 20% improvement) and in nonresponders [37].
  • In rheumatology the so-called "seronegative spondarthritis" is a group of diseases characterized by the presence of HLA-B 27 [38].

Analytical, diagnostic and therapeutic context of Rheumatology


  1. Skewed distribution of IgG Fc receptor IIa (CD32) polymorphism is associated with renal disease in systemic lupus erythematosus patients. Duits, A.J., Bootsma, H., Derksen, R.H., Spronk, P.E., Kater, L., Kallenberg, C.G., Capel, P.J., Westerdaal, N.A., Spierenburg, G.T., Gmelig-Meyling, F.H. Arthritis Rheum. (1995) [Pubmed]
  2. Guidelines for the medical management of osteoarthritis. Part I. Osteoarthritis of the hip.American College of Rheumatology. Hochberg, M.C., Altman, R.D., Brandt, K.D., Clark, B.M., Dieppe, P.A., Griffin, M.R., Moskowitz, R.W., Schnitzer, T.J. Arthritis Rheum. (1995) [Pubmed]
  3. Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. American College of Rheumatology. Kremer, J.M., Alarcón, G.S., Lightfoot, R.W., Willkens, R.F., Furst, D.E., Williams, H.J., Dent, P.B., Weinblatt, M.E. Arthritis Rheum. (1994) [Pubmed]
  4. Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial. Kaltwasser, J.P., Nash, P., Gladman, D., Rosen, C.F., Behrens, F., Jones, P., Wollenhaupt, J., Falk, F.G., Mease, P. Arthritis Rheum. (2004) [Pubmed]
  5. Determinants of serious liver disease among patients receiving low-dose methotrexate for rheumatoid arthritis. Walker, A.M., Funch, D., Dreyer, N.A., Tolman, K.G., Kremer, J.M., Alarcón, G.S., Lee, R.G., Weinblatt, M.E. Arthritis Rheum. (1993) [Pubmed]
  6. Learned helplessness in systemic lupus erythematosus: analysis using the Rheumatology Attitudes Index. Engle, E.W., Callahan, L.F., Pincus, T., Hochberg, M.C. Arthritis Rheum. (1990) [Pubmed]
  7. Physical activity as a determinant of bone conservation in the radial diaphysis in rheumatoid arthritis. Shawe, D., Hesp, R., Gumpel, J.M., Sambrook, P.N., Reeve, J. Ann. Rheum. Dis. (1993) [Pubmed]
  8. Group psychotherapy reduces illness intrusiveness in systemic lupus erythematosus. Edworthy, S.M., Dobkin, P.L., Clarke, A.E., Da Costa, D., Dritsa, M., Fortin, P.R., Barr, S., Ensworth, S., Esdaile, J.M., Beaulieu, A., Zummer, M., Senécal, J.L., Goulet, J.R., Choquette, D., Rich, E., Smith, D., Cividino, A., Gladman, D., Devins, G.M. J. Rheumatol. (2003) [Pubmed]
  9. The informationist: a prospective uncontrolled study. Sladek, R.M., Pinnock, C., Phillips, P.A. International journal for quality in health care : journal of the International Society for Quality in Health Care / ISQua. (2004) [Pubmed]
  10. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. Lovell, D.J., Giannini, E.H., Reiff, A., Cawkwell, G.D., Silverman, E.D., Nocton, J.J., Stein, L.D., Gedalia, A., Ilowite, N.T., Wallace, C.A., Whitmore, J., Finck, B.K. N. Engl. J. Med. (2000) [Pubmed]
  11. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. Bathon, J.M., Martin, R.W., Fleischmann, R.M., Tesser, J.R., Schiff, M.H., Keystone, E.C., Genovese, M.C., Wasko, M.C., Moreland, L.W., Weaver, A.L., Markenson, J., Finck, B.K. N. Engl. J. Med. (2000) [Pubmed]
  12. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. Weinblatt, M.E., Kremer, J.M., Bankhurst, A.D., Bulpitt, K.J., Fleischmann, R.M., Fox, R.I., Jackson, C.G., Lange, M., Burge, D.J. N. Engl. J. Med. (1999) [Pubmed]
  13. Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. The Methotrexate-Cyclosporine Combination Study Group. Tugwell, P., Pincus, T., Yocum, D., Stein, M., Gluck, O., Kraag, G., McKendry, R., Tesser, J., Baker, P., Wells, G. N. Engl. J. Med. (1995) [Pubmed]
  14. Glucosamine and chondroitin for treatment of osteoarthritis: a systematic quality assessment and meta-analysis. McAlindon, T.E., LaValley, M.P., Gulin, J.P., Felson, D.T. JAMA (2000) [Pubmed]
  15. Nephrotic-range proteinuria, the major risk factor for early atherosclerosis in juvenile-onset systemic lupus erythematosus. Falaschi, F., Ravelli, A., Martignoni, A., Migliavacca, D., Sartori, M., Pistorio, A., Perani, G., Martini, A. Arthritis Rheum. (2000) [Pubmed]
  16. Characteristics of Chinese patients with Wegener's granulomatosis with anti-myeloperoxidase autoantibodies. Chen, M., Yu, F., Zhang, Y., Zou, W.Z., Zhao, M.H., Wang, H.Y. Kidney Int. (2005) [Pubmed]
  17. Continuation of long term treatment with hydroxychloroquine in systemic lupus erythematosus and rheumatoid arthritis. Morand, E.F., McCloud, P.I., Littlejohn, G.O. Ann. Rheum. Dis. (1992) [Pubmed]
  18. Hypoxia inducible factor (HIF) in rheumatology: low O2! See what HIF can do! Gaber, T., Dziurla, R., Tripmacher, R., Burmester, G.R., Buttgereit, F. Ann. Rheum. Dis. (2005) [Pubmed]
  19. Screening for proteinuria in a rheumatology clinic: comparison of dipstick testing, 24 hour urine quantitative protein, and protein/creatinine ratio in random urine samples. Ralston, S.H., Caine, N., Richards, I., O'Reilly, D., Sturrock, R.D., Capell, H.A. Ann. Rheum. Dis. (1988) [Pubmed]
  20. Content comparison of occupation-based instruments in adult rheumatology and musculoskeletal rehabilitation based on the International Classification of Functioning, Disability and Health. Stamm, T.A., Cieza, A., Machold, K.P., Smolen, J.S., Stucki, G. Arthritis Rheum. (2004) [Pubmed]
  21. Genetic typing of patients with inflammatory arthritis at presentation can be used to predict outcome. Gough, A., Faint, J., Salmon, M., Hassell, A., Wordsworth, P., Pilling, D., Birley, A., Emery, P. Arthritis Rheum. (1994) [Pubmed]
  22. Rheumatoid arthritis susceptibility and interleukin 10: a study of two ethnically diverse populations. MacKay, K., Milicic, A., Lee, D., Tikly, M., Laval, S., Shatford, J., Wordsworth, P. Rheumatology (Oxford, England) (2003) [Pubmed]
  23. Chloroquine retinopathy: is there a safe daily dose? Marks, J.S. Ann. Rheum. Dis. (1982) [Pubmed]
  24. Treatment of dermatomyositis with methotrexate. Zieglschmid-Adams, M.E., Pandya, A.G., Cohen, S.B., Sontheimer, R.D. J. Am. Acad. Dermatol. (1995) [Pubmed]
  25. Impact of shoulder, elbow, and knee joint involvement on assessment of rheumatoid arthritis using the American College of Rheumatology Core Data Set. Tanaka, E., Saito, A., Kamitsuji, S., Yamada, T., Nakajima, A., Taniguchi, A., Hara, M., Tomatsu, T., Yamanaka, H., Kamatani, N. Arthritis Rheum. (2005) [Pubmed]
  26. Longterm outcome of treatment of Felty's syndrome with intramuscular gold: case reports and recommendations for management. Almoallim, H., Klinkhoff, A. J. Rheumatol. (2005) [Pubmed]
  27. Clinical outcome and predictors of disease evolution in patients with incomplete lupus erythematosus. Vilá, L.M., Mayor, A.M., Valentín, A.H., García-Soberal, M., Vilá, S. Lupus (2000) [Pubmed]
  28. Translation into Brazilian Portuguese, cultural adaptation and evaluation of the reliability of the Disabilities of the Arm, Shoulder and Hand Questionnaire. Orfale, A.G., Araújo, P.M., Ferraz, M.B., Natour, J. Braz. J. Med. Biol. Res. (2005) [Pubmed]
  29. Methotrexate in resistant juvenile rheumatoid arthritis. Results of the U.S.A.-U.S.S.R. double-blind, placebo-controlled trial. The Pediatric Rheumatology Collaborative Study Group and The Cooperative Children's Study Group. Giannini, E.H., Brewer, E.J., Kuzmina, N., Shaikov, A., Maximov, A., Vorontsov, I., Fink, C.W., Newman, A.J., Cassidy, J.T., Zemel, L.S. N. Engl. J. Med. (1992) [Pubmed]
  30. The American Board of Internal Medicine recertification program in rheumatology. Johanson, W.G., Moskowitz, R.W., Langdon, L.O. Arthritis Rheum. (1995) [Pubmed]
  31. Treatment of early seropositive rheumatoid arthritis with minocycline: four-year followup of a double-blind, placebo-controlled trial. O'Dell, J.R., Paulsen, G., Haire, C.E., Blakely, K., Palmer, W., Wees, S., Eckhoff, P.J., Klassen, L.W., Churchill, M., Doud, D., Weaver, A., Moore, G.F. Arthritis Rheum. (1999) [Pubmed]
  32. Pharmacokinetics, safety, and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis. Weinblatt, M.E., Kremer, J.M., Coblyn, J.S., Maier, A.L., Helfgott, S.M., Morrell, M., Byrne, V.M., Kaymakcian, M.V., Strand, V. Arthritis Rheum. (1999) [Pubmed]
  33. Treatment of early seropositive rheumatoid arthritis: a two-year, double-blind comparison of minocycline and hydroxychloroquine. O'Dell, J.R., Blakely, K.W., Mallek, J.A., Eckhoff, P.J., Leff, R.D., Wees, S.J., Sems, K.M., Fernandez, A.M., Palmer, W.R., Klassen, L.W., Paulsen, G.A., Haire, C.E., Moore, G.F. Arthritis Rheum. (2001) [Pubmed]
  34. Modulation of inflammation and metalloproteinase expression in synovial tissue by leflunomide and methotrexate in patients with active rheumatoid arthritis. Findings in a prospective, randomized, double-blind, parallel-design clinical trial in thirty-nine patients at two centers. Kraan, M.C., Reece, R.J., Barg, E.C., Smeets, T.J., Farnell, J., Rosenburg, R., Veale, D.J., Breedveld, F.C., Emery, P., Tak, P.P. Arthritis Rheum. (2000) [Pubmed]
  35. Genetic markers for the efficacy of tumour necrosis factor blocking therapy in rheumatoid arthritis. Padyukov, L., Lampa, J., Heimbürger, M., Ernestam, S., Cederholm, T., Lundkvist, I., Andersson, P., Hermansson, Y., Harju, A., Klareskog, L., Bratt, J. Ann. Rheum. Dis. (2003) [Pubmed]
  36. Osteoarthritis management: the role of cyclooxygenase-2-selective inhibitors. Schnitzer, T.J. Clinical therapeutics. (2001) [Pubmed]
  37. Serum cartilage oligomeric matrix protein (COMP) decreases in rheumatoid arthritis patients treated with infliximab or etanercept. Crnkic, M., Månsson, B., Larsson, L., Geborek, P., Heinegård, D., Saxne, T. Arthritis Res. Ther. (2003) [Pubmed]
  38. Traditional and new types of spondarthritis with special consideration of spondylodiscitis. Schilling, F., Stollenwerk, R., Dreher, R. Neurosurgical review. (1990) [Pubmed]
  39. Validity and reliability of the proposed American College of Rheumatology neuropsychological battery for systemic lupus erythematosus: comment on the article by Kozora et al. Hietaharju, A., Auvinen, A. Arthritis Rheum. (2005) [Pubmed]
  40. A randomized clinical trial of a psychoeducational intervention to improve outcomes in systemic lupus erythematosus. Karlson, E.W., Liang, M.H., Eaton, H., Huang, J., Fitzgerald, L., Rogers, M.P., Daltroy, L.H. Arthritis Rheum. (2004) [Pubmed]
  41. Filtration leukocytapheresis therapy in rheumatoid arthritis: a randomized, double-blind, placebo-controlled trial. Hidaka, T., Suzuki, K., Matsuki, Y., Takamizawa-Matsumoto, M., Kataharada, K., Ishizuka, T., Kawakami, M., Nakamura, H. Arthritis Rheum. (1999) [Pubmed]
  42. Abnormal vitamin B(6) status is associated with severity of symptoms in patients with rheumatoid arthritis. Chiang, E.P., Bagley, P.J., Selhub, J., Nadeau, M., Roubenoff, R. Am. J. Med. (2003) [Pubmed]
  43. The relationship of antiphospholipid antibodies to thromboembolic events in pediatric patients with systemic lupus erythematosus: a cross-sectional study. Berube, C., Mitchell, L., Silverman, E., David, M., Saint Cyr, C., Laxer, R., Adams, M., Vegh, P., Andrew, M. Pediatr. Res. (1998) [Pubmed]
WikiGenes - Universities